Role of human carbonic anhydrase isoforms VA and VB in obesity: Implications, mechanisms, and therapeutic prospects

被引:0
作者
Kacmaz, Muhammet [1 ]
Trawally, Muhammed [2 ]
Guzel-Akdemir, Ozlen [2 ]
机构
[1] Istanbul Univ, Inst Grad Studies Hlth Sci, Dept Pharmaceut Chem, TR-34126 Istanbul, Turkiye
[2] Istanbul Univ, Fac Pharm, Dept Pharmaceut Chem, TR-34116 Istanbul, Turkiye
来源
JOURNAL OF RESEARCH IN PHARMACY | 2024年 / 28卷 / 03期
关键词
Carbonic anhydrase; obesity; lipogenesis; gluconeogenesis; mitochondrial enzymes; INHIBITORS; TRANSMEMBRANE; TOPIRAMATE; EXPRESSION; HYPOXIA; TARGETS; IX; CONSEQUENCES; LOCALIZATION; PHENTERMINE;
D O I
10.29228/jrp.735
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
: Carbonic anhydrases (CAs, EC 4.2.1.1) are metalloenzymes ubiquitous in both prokaryotes and eukaryotes and catalyze a very basic physiological reaction. In particular, hCA VA and hCA VB isoenzymes are mitochondrial isoforms that are involved in metabolic processes such as ureagenesis, gluconeogenesis, and de novo lipogenesis by providing bicarbonate. The development of inhibitors for hCA VA and hCA VB commenced following the observation of weight loss, a metabolic adverse effect, in epileptic patients who were using antiepileptic medicines such as topiramate, zonisamide, and acetazolamide. Based on the structures of these drugs, the rational drug design technique, together with the famous "tail approach" was applied to develop novel hCA VA and hCA VB inhibitors that have potential as anti -obesity drug candidates. This review summarizes the implication of hCA VA and hCA VB in the pathophysiology of obesity and the inhibitory activities of small molecules developed against hCA VA and hCA VB as potential anti -obesity agents.
引用
收藏
页码:733 / 748
页数:16
相关论文
共 78 条
  • [1] Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX
    Abbate, F
    Casini, A
    Owa, T
    Scozzafava, A
    Supuran, CT
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (01) : 217 - 223
  • [2] Akdemir A., 2015, CARBONIC ANHYDRASES, P125, DOI [10.1016/B978-0-444-63258-6.00007-X, DOI 10.1016/B978-0-444-63258-6.00007-X]
  • [3] Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
    Alterio, Vincenzo
    Di Fiore, Anna
    D'Ambrosio, Katia
    Supuran, Claudiu T.
    De Simone, Giuseppina
    [J]. CHEMICAL REVIEWS, 2012, 112 (08) : 4421 - 4468
  • [4] Mitochondrial carbonic anhydrase VA and VB: properties and roles in health and disease
    Aspatwar, Ashok
    Supuran, Claudiu T.
    Waheed, Abdul
    Sly, William S.
    Parkkila, Seppo
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 2023, 601 (02): : 257 - 274
  • [5] Predictors of weight loss in adults with topiramate-treated epilepsy
    Ben-Menachem, E
    Axelsen, M
    Johanson, EH
    Stagge, A
    Smith, U
    [J]. OBESITY RESEARCH, 2003, 11 (04): : 556 - 562
  • [6] Bournat Juan C, 2010, Curr Opin Endocrinol Diabetes Obes, V17, P446, DOI 10.1097/MED.0b013e32833c3026
  • [7] Oxygen, a source of life and stress
    Brahimi-Horn, M. Christiane
    Pouyssegur, Jacques
    [J]. FEBS LETTERS, 2007, 581 (19) : 3582 - 3591
  • [8] Lead Development of Thiazolylsulfonamides with Carbonic Anhydrase Inhibitory Action
    Carta, Fabrizio
    Birkmann, Alexander
    Pfaff, Tamara
    Buschmann, Helmut
    Schwab, Wilfried
    Zimmermann, Holger
    Maresca, Alfonso
    Supuran, Claudiu T.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (07) : 3154 - 3164
  • [9] Chegwidden WR., 2021, The carbonic anhydrases: Current and emerging therapeutic targets, P1
  • [10] Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives
    Ciccone, Lidia
    Cerri, Chiara
    Nencetti, Susanna
    Orlandini, Elisabetta
    [J]. MOLECULES, 2021, 26 (21):